Analysis of Different Circulating Immune Cells in Patients With Recurrent Glioblastoma or Mixed Anaplasic Glioma Treated With Bevacizumab and Search for a Link With Response to Treatment

Trial Profile

Analysis of Different Circulating Immune Cells in Patients With Recurrent Glioblastoma or Mixed Anaplasic Glioma Treated With Bevacizumab and Search for a Link With Response to Treatment

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Glioblastoma; Glioma
  • Focus Biomarker; Pharmacodynamics
  • Acronyms AVA-CELL
  • Most Recent Events

    • 18 Aug 2015 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.
    • 02 Feb 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Mar 2015 to 1 Jun 2015.
    • 21 Jan 2014 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top